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Abstract
The timing of surgery for painful chronic pancreatitis (CP) may affect outcomes.
Clinical course, Izbicki pain scores, and pancreatic function were retrospectively compared and analyzed between patients
undergoing either early or late surgery (< 3 or ≥ 3 years from diagnosis) for painful CP in a single center from 2007 to 2012.
The early surgery group (n=98) more frequently than the late group (n=199) had abdominal pain with jaundice (22.4% vs 9.5%,
P= .002) and pancreatic mass +/ ductal dilatation (47% vs 27%, P< .001), but less frequently abdominal pain alone (73.5% vs
85.9%, P= .009), ductal dilatation alone (31% vs 71%, P< .001), parenchymal calciﬁcation (91.8% vs 100%, P< .001) or exocrine
insufﬁciency (60% vs 72%, P= .034); there were no other signiﬁcant differences. The early group had longer hospital stay (14.4 vs
12.2 days, P= .009), but no difference in complications. Signiﬁcantly greater pain relief followed early surgery (complete 69% vs 47%,
partial 22% vs 37%, none 8% vs 16%, P= .01) with lower rates of exocrine (60% vs 80%, P= .005) and endocrine insufﬁciency (36%
vs 53%, P= .033).
Our data indicate that early surgery results in higher rates of pain relief and pancreatic sufﬁciency than late surgery for chronic
pancreatitis patients. Frey and Berne procedures showed better results than other surgical procedures.
Abbreviations: CP = chronic pancreatitis, ISGPF = International Study Group on Pancreatic Fistulae, PD =
pancreaticoduodenectomy, POPF = postoperative pancreatic ﬁstula, PPPD = pylorus-preserving, SD = standard deviation.
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1. Introduction pancreatic parenchyma, chronic pain, local complicationsChronic pancreatitis (CP) is a progressive ﬁbro-inﬂammatory
disease of the pancreas with an increasing annual incidence
characterized by intractable pain and poor quality of life.[1] As
the disease progresses there is continuous destruction of theEditor: Jorg Kleeff.
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1(including duodenal, biliary and pancreatic duct obstruction,
and pancreatic pseudocysts), compromised pancreatic exocrine
and endocrine function, as well as an increased risk for pancreatic
cancer.[1,2] The associated co-morbidities, recurrent symptomatic
episodes, and socioeconomic impact make CP one of the most
resource intensive diseases to manage.[3]
One key goal of the management of CP is to mitigate pain,[1,4–
6] as it is the predominant symptom and its severity signiﬁcantly
correlates with poor quality of life.[7] Unfortunately, the
mechanisms of pain secondary to CP have not been fully
elucidated, resulting in suboptimal clinical efﬁcacy of targeted
treatments.[4] Traditionally, a conservative step-up approach has
been advocated to treat painful CP, with surgery regarded as an
optionwhen other treatments have failed.[1,5,6] The initial choices
of analgesic medications are nonsteroidal anti-inﬂammatory
drugs.[4] But, a large proportion of patients prove refractory to
medical therapy.[8] Endoscopic therapy is often performed in
such patients in an effort to relieve pancreatic and/or bile duct
obstruction and symptomatic pseudocysts.[1,5,6] Randomized
controlled studies,[9–11] however, have shown that surgery (either
resection or drainage) results in signiﬁcantly greater and more
durable pain relief than endotherapy.[10,11]
There is some evidence to suggest that early surgery is more
effective than later surgery in preserving exocrine function in
experimental CP.[12] A recent meta-analysis has shown that early
surgery is associated with an increased likelihood of complete
pain relief together with reduced rates of pancreatic insufﬁciency
and re-intervention.[13] A multicentre retrospective study of 266
patients with CP demonstrated that early surgery within 3 years
was more beneﬁcial for pain relief, pancreatic function, and
quality of life.[14] Nevertheless other studies suggest or advocate a
step-up approach using antioxidants,[15–18] adjuvant analge-
sics,[19] pancreatic enzyme supplements,[20,21] and endoscopy
[6,21]
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fail the conservative management.
To determine the relative merits of early and late surgery we
analyzed 297 patients who had surgery for CP retrospectively to
determine[1] whether early surgery offered better pain control and
preservation of pancreatic function than late surgery, and[2]
which surgical procedure (resection only or resection +/
drainage or drainage only) was more effective when performed
early.2. Methods
2.1. Patients and data collection
Consecutive CP patients diagnosed by disease history and
radiological ﬁndings who underwent surgery at West China
Hospital between February 2007 and February 2012 were
considered for inclusion in this retrospective study. Demo-
graphics, symptoms at admission, pancreatic functional status,
surgical procedures undertaken, intra- and postoperative out-
comes were determined. Risk factors for CP were classiﬁed
according to the TIGAR-O classiﬁcation system.[22] Patients were
excluded from the study if the diagnosis of CP was not conﬁrmed
histologically, if pancreatic cancer was detected on histology, if
there was inadequate information or patients were lost to follow-
up during 3 years after surgery. Patients were also excluded if
they had any surgical procedures on the pancreas prior to the
index operation for CP. All the identiﬁed patients were followed-
up in outpatient clinic and/or by telephone for at least 3 years
postoperatively. The research protocol was approved by the
institutional review board of West China Hospital and informed
consent from patients was waived due to retrospective use of
anonymized data. The study followed the STROBE guidelines.
2.2. Patient management and surgical procedures
Patients in West China Hospital with a disease history of CP
conﬁrmed radiologically (CT and/or MRI) and with intractable
pain are candidates for surgery; we have used narcotic analgesia
and endotherapy with surgery as an alternative or subsequently,
depending on clinical and radiological features. Pancreaticoduo-
denectomy (PD) and pylorus-preserving pancreaticoduodenec-
tomy (PPPD) were offered for inﬂammatory enlargement of
the pancreatic head, especially when calciﬁcations were pre-
dominantly in the head. Beger’s procedure was offered for
calciﬁcations located in the head of the pancreas with or without
associated enlargement of the pancreatic head; the Berne
procedure was an alternative determined intraoperatively. Frey’s
procedure was offered when calciﬁcations were located through-
out the pancreas with or without pancreatic head enlargement,
and with or without a dilated main pancreatic duct. The
Partington–Rochelle procedure was undertaken as an alternative
for a dilated main pancreatic duct in patients with no pancreatic
head enlargement.
2.3. Outcome measures
The primary endpoint was pain relief, assessed at the end of
follow-up using the Izbicki pain score as described by Cahen
et al,[10] withminormodiﬁcations and as reported by the patients.
It was deﬁned as complete pain relief (Izbicki pain score,  10 or
pain level decrease of 100%), partial (Izbicki pain score > 10
and pain level decrease > 50%) or no relief (Izbicki pain score
> 10 and pain level decrease of<50%).2Secondary end points were intra- and postoperative outcomes
including pancreatic function. Postoperative pancreatic ﬁstula
(POPF) was deﬁned by the International Study Group on
Pancreatic Fistulae (ISGPF A, B, and C) deﬁnition.[23] Exocrine
insufﬁciency was deﬁned as faecal elastase levels <200mg/g, or
the presence of steatorrhoea, or the need for pancreatic enzyme
replacement therapy (>1 year history; overt steatorrhoea without
treatment). Endocrine insufﬁciency was deﬁned by the presence
of prediabetes (fasting serum glucose levels >6.0mmol/L in
capillary blood or >6.9mmol/L in venous plasma on 2 different
days) or overt diabetes mellitus. Both exocrine insufﬁciency and
endocrine insufﬁciency were deﬁned as described by Cahen
et al[10]; those who had pancreatic insufﬁciency at both baseline
and follow-up (insufﬁciency persisted); those who did not have
insufﬁciency at baseline but in whom insufﬁciency developed
during follow-up (insufﬁciency developed); those who had
insufﬁciency at baseline but not at follow-up (insufﬁciency
resolved), and those who did not have insufﬁciency at baseline or
follow-up (sufﬁciency persisted). Quality of life was measured by
the European Organisation for Research and Treatment of
Cancer’s quality-of-life questionnaire.[24]2.4. Statistical analysis
Based on data from previous studies,[14,25] early surgery was
deﬁned as surgery performed  3 years following diagnosis,
while late surgery was >3 years. Continuous data are presented
as mean± standard deviation (SD) or median with range
depending on normal or skewed distributions, respectively.
Categorical variables are described as numbers and in percen-
tages. Mann–Whitney U and Chi-square (or Fisher’s exact test)
tests were used for continuous and categorical data comparisons,
respectively. Intension-to-treat analysis was performed before
removal of died patients before follow-up. A P value <.05 was
considered to be statistically signiﬁcant. The analyses were
performed using IBM SPSS 22.0 statistical software (IBM,
Armonk, NY).3. Results
3.1. Characteristics of included patients
The patient selection process is shown in Figure 1. The initial
screen included 417 CP patients. Eighty patients were excluded
because they were lost to follow-up or there was insufﬁcient
information to determine long-term outcome. A further 31
patients were excluded either because of pancreatic/peri-
ampullary cancer, or they had undergone previous surgery, or
histopathology was not obtained. A total of 306 patients with CP
were included. Four patients died postoperatively in the early
surgery group before follow-up: 2 abdominal cavity bleeding
after PD, 1 gastrointestinal bleeding after PPPD, 1 gastrointesti-
nal leakage (abdominal cavity infection and respiratory failure)
after Beger’s procedure; 4 died in the late surgery group: 2
gastroduodenal artery rupture after PD, 1 lung infection after PD,
1 liver and renal failure after Beger’s procedure. Thus complete
data were available for analysis from 297 patients. The year in
which surgery was performed had no signiﬁcant impact on the
allocation of early or late surgery group (each year P> .05). The
preoperative patient characteristics are outlined in Table 1. There
were no statistically signiﬁcant differences in age, gender,
TIGAR-O classiﬁcation, pain pattern and endocrine insufﬁcien-
cy, and the presence of both pancreatic head mass and ductal
Table 1
Characteristics of CP patients prior to surgery.
Patient characteristics Total n=297
Gender, n (%)
Male 216 (72.7)
Female 81 (27.3)
Age in years, mean ± SD 47±12.4
Symptoms
Abdominal pain alone 243 (81.8)
Abdominal pain + jaundice 41 (13.8)
Abdominal pain + diarrhoea 8 (2.7)
Abdominal pain + black pool 5 (1.7)
Key radiological appearance
Mass alone 48 (16.2)
Ductal dilatation 171 (57.6)
Mass + ductal dilatation 51 (17.2)
Ductal stone without dilatation or mass 27 (9.1)
Parenchymal calciﬁcation 289 (97.3)
TIGAR-O classiﬁcation, n (%)
Toxic-metabolic (alcohol and smoking) 118 (39.7)
Idiopathic 142 (47.8)
Hereditary 1 (0.3)
Autoimmune 1 (0.3)
Recurrent or severe acute pancreatitis 23 (7.7)
Obstructive 7 (2.4)
Others 5 (1.7)
Pain pattern, n (%)
Continuous 174 (58.6)
Intermittent 123 (41.4)
Exocrine function, n (%)
Insufﬁciency 203 (68.4)
Normal 94 (31.7)
Endocrine function, n (%)
Insufﬁciency 87 (29.3)
Normal 210 (70.7)
∗
Early vs late.
SD= standard deviations.
P value in bold indicates early vs late was signiﬁcant different at level of 0.05.
Patients included for more detailed 
evaluation n = 337
Histopathologically confirmed chronic 
pancreatitis n = 306
Patients excluded: n = 80
Lost to follow-up: 52
Inadequate information: 28
Patients excluded: n = 31
Previous surgery: 17
Developed cancer: 11
No histopathology: 3
Chronic pancreatitis patients diagnosed 
by disease history and radiology n = 417
Figure 1. Patient selection ﬂow chart.
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3dilatation between the early and late surgery groups. There was a
higher proportion of patients in the early surgery group who had
abdominal pain with jaundice (22.4% vs 9.5%, P= .002),
pancreatic head mass (26.5% vs 11.1%) or pancreatic duct stone
without ductal dilatation or mass (20.4% vs 15.6%), but lower
proportion with abdominal pain alone (73.5 vs 85.9%),
pancreatic duct dilatation alone (30.6% vs 70.9%) and
parenchymal calciﬁcation (91.8% vs 100%) when compared
to the late surgery group (all P< .05). The proportion of patients
with exocrine insufﬁciency was signiﬁcantly lower in the early
surgery group as compared to the late surgery group (60.2% vs
72.4%, P= .034), while there was no difference in endocrine
sufﬁciency (25.5% vs 31.2%, P>0.05).
3.2. Intra- and postoperative complications
Patients underwent surgery at a median 25months (range 11–36)
from initial CP diagnosis in the early surgery group compared
with 81 months (range 45–122) in the late surgery group. There
was no difference in follow-up time between the 2 surgery groups
(65 months [36–96] vs 73 months [36–89], P> .05). Details of
the intra- and postoperative complications and length of hospital
stay are provided in Table 2. There were no signiﬁcant differences
in the mean operation time, intraoperative blood transfusion,
volume of transfused packed red blood cells and the overallEarly n=98 Later n=199 P value
∗
.450
74 (75.5) 142 (71.4)
24 (24.5) 57 (28.6)
47.2±11.3 48±9.2 .521
72 (73.5) 171 (85.9) .009
22 (22.4) 19 (9.5) .002
2 (2) 6 (3) 1.000
2 (2) 3 (1.5) .666
26 (26.5) 22 (11.1) .001
30 (30.6) 141 (70.9) < .001
20 (20.4) 31 (15.6) .299
22 (22.4) 5 (2.5) < .001
90 (91.8) 199 (100) < .001
.870
37 (37.8) 81 (40.7)
49 (50) 93 (46.7)
0 (0) 1 (0.5)
1 (1) 0 (0)
7 (7.1) 16 (8)
2 (2) 5 (2.5)
2 (2) 3 (1.5)
.517
60 (61.2) 114 (57.3)
38 (38.8) 85 (42.7)
0.034
59 (60.2) 144 (72.4)
39 (39.8) 55 (27.6)
0.315
25 (25.5) 62 (31.2)
73 (74.5) 137 (68.8)
Table 2
Comparisons of intra- and postoperative outcomes.
Parameters Early n=98 Later n=199 P value
Intraoperative blood transfusion, n (%) 22 (22.5) 41 (20.6) .714
Volume of packed red cells in ml, mean ± SD 380±104 402±128 .141
Intensive care unit stay in days, mean ± SD 1.8±3.1 1.4±2.5 .233
Complications, n (%) 21 (21.4) 33 (16.6) .309
Haemorrhage 4 (4.1) 7 (3.5) .809
Re-laparotomy 4 (4.1) 6 (3) .632
POPF (ISGPF A) 13 (13.2) 14 (7) .079
POPF (ISGPF B/C) 5 (5.1) 6 (3.0) .514
Infection 5 (5.1) 9 (4.5) .825
Hospital stay in days, mean±SD 14.4±8 12.2±6.1 .009
Izbicki pain score
∗
24±14 31±16 .031
Pain relief
∗
, n (%) .010
No relief 8 (8.2) 32 (16.1)
Partial relief 22 (22.4) 74 (37.2)
Complete relief 68 (69.4) 93 (46.7)
Exocrine function
∗
, n (%) .005
Insufﬁciency persisted 46 (46.9) 133 (66.8)
Insufﬁciency developed 13 (13.3) 23 (11.6)
Insufﬁciency resolved 13 (13.3) 11 (5.5)
Sufﬁciency persisted 26 (26.5) 32 (16.1)
Endocrine function
∗
, n (%) .033
Insufﬁciency persisted 20 (20.4) 58 (29.1)
Insufﬁciency developed 15 (15.3) 47 (23.6)
Insufﬁciency resolved 5 (5.1) 4 (2)
Sufﬁciency persisted 58 (59.2) 90 (45.2)
Global quality of life 73.14 (0–100) 62.76 (0–89) .004
ISGPF= International Study Group of Pancreatic Fistula, POPF=postoperative pancreatic ﬁstulae, SD= standard deviations.
∗
Assessed at follow-up as indicated in the Methods section.
Ke et al. Medicine (2018) 97:19 Medicinecomplication rate between the 2 groups. The early surgery group
had a higher incidence of grade A POPF (13.2% vs 7%, P= .079)
andwas associated with a longer hospital stay (mean 14.4 vs 12.2
days, P= .009) compared to the late surgery group.3.3. Endpoints
Izbicki pain scores at follow-up were signiﬁcantly lower in the
early surgery group compared to the late surgery group (24±14
vs 31±16, P= .031; Table 2). Complete or partial pain relief was
achieved in 91.8% of patients in the early surgery group,
signiﬁcantly higher than 83.9% in the late surgery group
(P= .01). A much higher proportion of patients in the early
surgery group had complete pain relief (69.4% vs 46.7%,
P< .001), and the proportion of patients with no pain relief in the
early surgery group was smaller (8.2% vs 16.1%, P= .06).
Early surgery was followed by a reduced incidence of exocrine
insufﬁciency (60.2% vs 80.39%, P= .005) and endocrine
insufﬁciency (35.7% vs 52.7%, P= .033), with a trend of a higher
rate of resolution of both exocrine and endocrine insufﬁciency in
the early surgery group (Table 2). Early surgery group also showed
a better quality of life than later surgery group (Table 2).3.4. Comparison of the impact of individual surgical
procedures on pain relief
The inﬂuence of different surgical procedures on postoperative
pain relief in the early and late surgery groups was analyzed and is
summarized in Table 3. There were no signiﬁcant differences in
pain relief between the early and late surgery groups when only
resections (PD, PPPD and Beger’s procedure) or drainage
procedures (Partington–Rochelle) were compared. In contrast,4patients undergoing a combination of resection with drainage
(Frey and Berne procedures) experienced signiﬁcantly greater
pain relief in the early surgery group compared to the late surgery
group (Frey P= .031, Berne P= .028). There were no statistically
signiﬁcant differences in pain relief between different early
surgical interventions likely due to small patient numbers. There
was however a trend toward complete pain relief following Frey
(82.6%), Berne (75.9%), and Partington–Rochelle (70%)
procedures when compared with other procedures (50%–
61.5%).3.5. Comparison of individual surgical procedures on
pancreatic function
The impact of different surgical procedures on postoperative
pancreatic exocrine and endocrine function is summarized in
Table 4. Similar to the ﬁndings obtained for pain relief, patients
undergoing Frey and Berne procedures in the early surgery group
had consistently high rates of exocrine (Frey P= .001, Berne
P= .02) and endocrine (Frey P= .037, Berne P= .049) function
preservation when compared with patients undergoing the same
procedures in the late surgery group. This was not the case for the
other surgical procedures, with the exception of patients
undergoing Beger’s procedure in the early surgery group who
had signiﬁcantly better preservation of endocrine function
(P= .038). Intention-to-treat analyses including patients who
died did not change any ﬁndings on endpoints.4. Discussion
Our study clearly demonstrates that early surgery results in more
effective pain relief and better preservation of pancreatic exocrine
Table 3
Comparison of individual surgical procedures performed early or late on pain relief.
Procedures No relief Partial relief Complete relief P value
Resection, n (%)
PD 1.000
Early (n=9) 1 (11.1) 3 (33.3) 5 (55.6)
Late (n=19) 4 (21.1) 5 (26.3) 10 (52.6)
PPPD .704
Early (n=13) 2 (15.4) 3 (23.1) 8 (61.5)
Late (n=18) 3 (16.7) 7 (38.9) 8 (44.4)
Beger .436
Early (n=14) 1 (7.1) 6 (42.9) 7 (50)
Late (n=35) 8 (22.9) 12 (34.3) 15 (42.9)
Resection + drainage, n (%)
Frey .031
Early (n=23) 0 (0) 4 (17.4) 19 (82.6)
Late (n=30) 5 (16.7) 10 (33.3) 15 (50)
Berne .028
Early (n=29) 3 (10.3) 4 (13.8) 22 (75.9)
Late (n=69) 9 (13) 27 (39.1) 33 (47.8)
Drainage, n (%) .328
Partington–Rochelle
Early (n=10) 1 (10) 2 (20) 7 (70)
Late (n=28) 3 (10.7) 13 (46.4) 12 (42.9)
PD=pancreaticoduodenectomy, PPPD=pylorus-preserving pancreaticoduodenectomy.
P value in bold indicates early vs late for Frey and Berne was signiﬁcant different at level of 0.05, respectively.
Ke et al. Medicine (2018) 97:19 www.md-journal.comand endocrine function. The study, the largest comparing early
versus late surgery for painful CP to date, also demonstrates that
drainage and resection (e.g., Frey and Berne procedures) had
better outcomes than resection or drainage alone.
The early surgery group was comparable to the late surgery
group with respect to the operation time, intraoperative blood
transfusion, transfused red volume of packed blood cells,
duration of intensive care unit stay, and the overall complicationTable 4
Comparison of individual surgical procedures performed early or lat
Exocrine function
Procedures
Insufﬁciency
persisted
Insufﬁciency
developed
Insufﬁciency
resolved
Sufﬁciency
persisted
Resection, n (%)
PD
Early (n=9) 5 (62.5) 3 (25.0) 0 (0) 0 (0)
Late (n=19) 12 (63.2) 4 (21.1) 0 (0) 3 (15.8)
PPPD
Early (n=13) 8 (57.1) 3 (21.4) 2 (14.3) 1 (7.1)
Late (n=18) 12 (63.2) 2 (10.5) 1 (5.3) 4 (21.1)
Beger
Early (n=14) 7 (50) 2 (14.3) 3 (21.43) 2 (14.3)
Late (n=35) 22 (62.9) 5 (14.3) 3 (8.6) 5 (14.3)
Resection + drainage, n (%)
Frey
Early (n=23) 10 (43.5) 0 (0) 3 (13) 10 (43.5)
Late (n=30) 22 (73.3) 3 (10) 1 (3.3) 4 (13.3)
Berne
Early (n=29) 11 (37.9) 3 (10.3) 4 (13.8) 11 (37.9)
Late (n=69) 47 (68.1) 7 (10.1) 4 (5.8) 11 (15.9)
Drainage, n (%)
Partington–Rochelle
Early (n=10) 5 (50) 2 (20) 1 (10) 2 (20)
Late (n=28) 18 (66.7) 2 (7.4) 2 (7.4) 5 (18.5)
PD=pancreaticoduodenectomy, PPPD=pylorus-preserving pancreaticoduodenectomy.
5rate, which indicate that it was safe. The incidence of POPF B/C
was similar in both groups, but early surgery was associated with
a higher incidence of POPF A, and thus with a longer hospital
stay. This may be because in CP at an earlier stage the pancreas
tends to have more functional units, less ﬁbrosis (soft pancreas)
and the exocrine pancreas is able to produce more ﬂuid. It has
been demonstrated that the soft pancreas has a higher POPF rate
after surgery than the hard pancreas.[26]e on exocrine and endocrine function.
Endocrine function
P value
Insufﬁciency
persisted
Insufﬁciency
developed
Insufﬁciency
resolved
Sufﬁciency
persisted P value
.630 .874
3 (37.5) 3 (37.5) 0 (0) 2 (25.0)
6 (31.6) 6 (31.6) 0 (0) 7 (36.8)
.524 1.000
5 (35.7) 4 (28.6) 0 (0) 5 (35.7)
6 (31.6) 5 (26.3) 0 (0) 8 (42.1)
.582 .038
2 (14.3) 0 (0) 2 (14.3) 10 (71.4)
12 (34.3) 7 (20) 1 (2.9) 15 (42.9)
.011 .037
4 (17.4) 1 (4.3) 3 (13) 15 (65.2)
9 (30) 8 (26.7) 1 (3.3) 12 (40)
.020 .049
3 (10.3) 4 (13.8) 0 (0) 22 (75.9)
21 (30.4) 14 (20.3) 1 (1.4) 33 (47.8)
.644 .626
3 (30) 3 (30) 0 (0) 4 (40)
4 (14.8) 7 (25.9) 1 (3.7) 15 (55.6)
Ke et al. Medicine (2018) 97:19 MedicineA major challenge in the management of CP patients is the
treatment of pain.[4] The pain in CP is multifactorial with a
number of proposed mechanisms, although by the time patients
present there is often a signiﬁcant neuropathic component.[27]
Neural plasticity, neural inﬂammation, and an altered distribu-
tion of sympathetic and sensory ﬁbres are seen in CP and these
changes correlate with the severity of neuropathic pain.[28]
Patients with CP exhibit central hyperalgesia and alterations in
brain resting activity, which decrease their pain threshold.[28]
Traditionally it was considered that pain in CP would ultimately
resolve spontaneously or “burn out,” owing to progressive
destruction of the pancreatic parenchyma.[29] More recent data
indicate that repeated episodes of pancreatic inﬂammation lead to
peripheral and central nociceptive nerve sensitisation, which
leads to a chronic pain state that might be avoided by earlier
intervention.[30] Narcotic analgesics commonly used to treat
unresolved pain are associated with addiction and unfavourable
side effects, including opioid hyperalgesia. Recent meta-analyses
indicate that the antineuropathic pain medications pregablin,[31]
antioxidants,[16,32,33] and pancreatic enzyme replacement thera-
py[34] have little effect on pain relief. An improved understanding
of the patterns of pain in CP is needed and the Dutch CARE
trial,[35] presently underway, seeks to address this.
CP patients in whom pain is refractory to medications and
endotherapy eventually undergo surgery, often as a last
resort.[1,5,6] Recently, surgery has been shown to be superior
to endotherapy for both short- and long-term pain control in
randomized trials,[9–11] conﬁrmed in a meta-analysis based on
these trials.[36] Intermediate and long-term follow-up studies[37–
42] have shown that patients undergoing resection with or
without drainage procedures have sustained pain relief with
substantially improved quality of life. Our CP patients who had
intractable pain followingmedical management and endotherapy
were advised to have surgery; in our study, the complete and
partial pain relief rates were similar to or higher than in previous
studies. We used a cut-off of 3 years to deﬁne early and late
surgery, in keeping with previous studies;[14,25] many of our
patients had little response to medical management and had
undergone one or more endoscopic interventions by this time.
Other studies have suggested that surgical intervention prior to
the start of opioid dependence might be beneﬁcial,[38,43] but this
could be considered too early to justify a major operation;
nevertheless, a higher number of preceding endoscopic inter-
ventions is associated with a worse outcome.[14,38]
A further challenge in the management of CP patients is the
preservation of pancreatic function, dependent in some patients
on life style modiﬁcation. Nealon and Thompson[44] have shown
in a small randomized trial that surgical drainage (modiﬁed
Puestow procedure) was better than conservative management in
preserving pancreatic function. In our study the overall rate of
exocrine and endocrine insufﬁciency was 72.4% and 47.1%,
respectively, lower than previous published work, possibly due to
a shorter follow-up time. There was a signiﬁcantly lower
incidence of exocrine insufﬁciency in the early surgery group
prior to surgery, and early surgery was associated with more
frequent preservation of pancreatic function, in keeping with
previous studies.[14,25,36] This ﬁnding may simply be attributed to
CP that is not as advanced, but drainage and/or resection can
remove obstruction and restore pancreatic secretion, preventing
further pancreatic damage. Exocrine insufﬁciency commonly
develops 5 to 10 years after the onset of CP, accompanying
progressive destruction of the gland, but tends to be under-
diagnosed and is under-treated in CP patients;[5] early surgery6may help to correct this. CP may also lead to type 3c diabetes
mellitus and patients with long-standing diabetes mellitus may
develop CP.[5] CP is a known risk factor for pancreatic cancer and
diabetes mellitus may increase that risk;[45] surgery in CP may
reduce this risk. In a study by Ueda et al[46] of 87 patients who
underwent surgical drainage of the pancreas, only 1 patient
developed pancreatic cancer, with no cancers developing in 125
patients who underwent pancreatic resection. Of 352 patients
who did not undergo surgery, however, 18 developed pancreatic
cancer.
The choice of surgical procedure is important and there are a
signiﬁcant number of randomized controlled trials comparing the
different options. In this study, the choice of procedure was based
on radiological morphology and surgeon preference. A recent
meta-analysis[47] suggested that duodenum-preserving pancreatic
resection (Beger’s or Frey procedures) had similar outcomes to
PD with respect to mortality, adverse events and quality of life,
but may be associated with a shorter hospital stay and less blood
loss. A further meta-analysis[48] showed that the Frey procedure
is safe and effective, which when compared to PD is followed by
fewer overall complications and better short and long term pain
relief, pancreatic function preservation and quality of life.
Compared with Beger’s procedure, the Frey procedure had a
reduced operation time and was associated with lower morbidi-
ty.[48] Our study corroborates these ﬁndings and suggests that
resection plus drainage procedures (both Frey and Berne
procedures) had better outcomes when performed early.
This study has several limitations. It was performed retrospec-
tively and the sample sizes in the individual surgical groups were
small, which may have resulted in some bias. The early and late
surgical groups did have differences prior to surgery, especially in
pancreatic morphology, but this has been shown not to relate to
pain severity or the response to intervention. We did not obtain
precise data for symptom onset, narcotic medicine and
endotherapy prior to operation for comparisons. Data on quality
of life, one of the better parameters to assess treatment effects in
CP, were not available. The validated PANQOLI tool is now
available and should be used in future studies. The results of the
prospective, multicenter randomized controlled trial comparing
early surgery and an optimised step-up approach are eagerly
awaited.[49] Unfortunately this trial has used the Izbicki pain
score, as in the present study, which assesses only 4 aspects of
pain.[10] A more comprehensive pain assessment tool is required
to capture all important aspects of pain, since pain is the primary
indication for intervention and the reduction of pain is the
primary endpoint of intervention studies.[50] While our data
indicate the beneﬁts of early surgery and the surgical procedures
that are most effective, these ﬁndings need to be conﬁrmed in
prospective randomized controlled trials.Author contributions
Writing – original draft: Nengwen Ke, Wei Huang.
Writing – review & editing: Dan Jia, Quentin M Nunes, John A
Windsor, Xubao Liu, Robert Sutton.References
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